- Cosmeceutical
industry forecasts anticipate $73 billion market for cosmetic skin care
products utilizing active chemical ingredients by 2023
- Therma
Bright is using trademarked infrared head technologies to target skin
viruses and establish a protective barrier for the human body’s largest
organ
- Company
is also exploring cannabidiol’s properties as augmenting agent for thermal
technologies in fighting pain
Far from being mere tissue, skin is the human body’s largest
and fastest-growing organ and a vital protection against harm to all of the
body’s other organs and the systems that regulate their function (http://ibn.fm/4AO39), which
provides an obvious reason for trying to keep skin healthy. Therma Bright Inc.
(TSX.V: THRM) (OTC: THRBF) is focusing its business mission on the development
of innovative technologies that strengthen and sustain the body’s outer layer
and help people to live healthier lives as a result.
The key to Therma Bright’s vision of enhancing health and
wellness is to employ trademarked infrared heat technology against agents that
attack the skin, such as insect stings, bites and viruses. The company’s
TherOZap technology is a first-generation medical device approved by the U.S.
Food and Drug Administration (“FDA”) for the relief of the symptoms of skin
pain, itch and inflammation, but Therma Bright has been working on a corollary
product that may establish a barrier against stinging and biting insects to
combat the Zika virus and other mosquito-borne diseases such as dengue.
Therma Bright is testing final prototypes of the technology
against the Zika virus at a research laboratory in a process that’s expected to
take several months (http://ibn.fm/KlXYA).
Initial pre-clinical test results announced last year, when the company was
named Jenex, indicated that Toronto, Canada’s Techna Institute had found
TherOZap effective for the inactivation of live Zika virus in culture media and
the inhibition of Zika virus infection into cultured cells in vitro, according
to a company news release (http://ibn.fm/gSwaT).
Those findings led Robert A. Poggie, a regulatory consultant
for the FDA, to declare, “Pre-clinical testing of the TherOZap technology
indicates effectiveness in inhibiting Zika virus, which holds promise for the
US FDA accepting marketing claims and associated data via 510(k) review,”
according to the news release.
A second trademarked Therma Bright technology, InterceptCS,
has also received some regulatory recognition for the treatment of cold sores
by killing cells infected with the herpes simplex Type 1 virus. Based on a
double-blind placebo study, InterceptCS is approved for the claim, “For prevention
of cold sores when used within three hours of the onset of the prodrome” by
Health Canada. The InterceptCS technology is not, however, approved by the
United States’ FDA for any claim of clinical indication, clinical efficacy
and/or cure or prevention of disease at this time.
InterceptCS delivers controlled topical heat with no risk of
burning the skin as it targets the cold sore virus-infected cells. The
company’s technologies are representative of a broader cosmeceutical industry
that produces products with cosmetic applications of active potential chemical
ingredients.
Industry forecasts anticipate a growing worldwide market for
cosmeceuticals, with one prediction forecasting growth at a CAGR of 8.21
percent between 2017 and 2023, when the market is expected to reach about $73
billion (http://ibn.fm/q6Ew2).
Therma Bright is also turning to the positive word of mouth
surrounding cannabidiol (“CBD”) for testing the cannabis plant-derived active
ingredient in concert with the company’s thermal products as a means of
enhancing pain relief therapies (http://ibn.fm/5mAes).
For more information, visit the company’s website at www.ThermaBright.com
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment